

REPROS THERAPEUTICS INC.  
Form 8-K  
November 10, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report  
(Date of earliest event reported): November 10, 2008  
Repros Therapeutics Inc.  
(Exact name of registrant as specified in its charter)**

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**001-15281**  
(Commission File Number)

**76-0233274**  
(I.R.S. Employer Identification  
No.)

**2408 Timberloch Place, Suite B-7  
The Woodlands, Texas 77380**  
(Address of principal  
executive offices  
and zip code)

**(281) 719-3400**  
(Registrant's telephone  
number, including area  
code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02 Results of Operations and Financial Condition**

On November 10, 2008, Repros Therapeutics Inc. (the Company ) announced financial results for the third quarter ended September 30, 2008. Additional information is included in the Company s press release dated November 10, 2008, which is attached hereto as Exhibit 99.1.

The information in this Item 2.02 of this Current Report is being furnished pursuant to Item 2.02 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Item 2.02 of this Current Report shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 of this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933.

**Item 9.01. Financial Statements and Exhibits**

d. Exhibits

Exhibit Number	Description
99.1	Press Release dated November 10, 2008

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: November 10, 2008

By: /s/ Louis Ploth, Jr.  
Louis Ploth, Jr.  
Vice President, Business Development  
and  
Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press Release dated November 10, 2008